β-Sitosterol as a Promising Anticancer Agent for Chemoprevention and Chemotherapy: Mechanisms of Action and Future Prospects
Advances in Nutrition · 2023-09 · 14 (5) · 1085-1110
DOI: 10.1016/j.advnut.2023.05.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Nutrition, 2023-09. Verfasst von Haoyu Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Prostatic Neoplasms. Die Arbeit wurde bisher 154-mal zitiert (Crossref) und nennt 276 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cancer is one of the primary causes of death worldwide, and its incidence continues to increase yearly. Despite significant advances in research, the search for effective and nontoxic preventive and therapeutic agents remains greatly important. Cancer is a multimodal disease, where various mechanisms play significant roles in its occurrence and progression. This highlights the need for multitargeted approaches that are not only safe and inexpensive but also provide effective alternatives for current therapeutic regimens. β-Sitosterol (SIT), the most abundant phytosterol found in various plant foods, represents such an option. Preclinical evidence over the past few decades has overwhelmingly shown that SIT exhibits multiple anticancer activities against varied cancers, such as liver, cervical, colon, stomach, breast, lung, pancreatic, and prostate cancers, in addition to leukemia, multiple myeloma, melanoma, and fibrosarcoma. In this article, we present the latest advances and perspectives on SIT-systematically summarizing its antitumor mechanisms of action into 7 main sections and combining current challenges and prospects-for its use as a promising agent for cancer prevention and treatment. In particular, SIT plays a role in cancer prevention and treatment mainly by enhancing apoptosis, inducing cell cycle arrest, bidirectionally regulating oxidative stress, improving metabolic reprogramming, inhibiting invasion and metastasis, modulating immunity and inflammation, and combating drug resistance. Although SIT holds such great promise, the poor aqueous solubility and bioavailability coupled with low targeting efficacy limit its therapeutic efficacy and clinical application. Further research on novel drug delivery systems may improve these deficiencies. Overall, through complex and pleiotropic mechanisms, SIT has good potential for tumor chemoprevention and chemotherapy. However, no clinical trials have yet proven this potential. This review provides theoretical basis and rationality for the further design and conduct of clinical trials to confirm the anticancer activity of SIT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
- Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China. Electronic address: dr_hongli@whu.edu.cn.
Zitieren
APA
Wang, H., Wang, Z., Zhang, Z., Liu, J., & Hong, L. (2023). β-Sitosterol as a Promising Anticancer Agent for Chemoprevention and Chemotherapy: Mechanisms of Action and Future Prospects. Advances in Nutrition, 14(5), 1085-1110. https://doi.org/10.1016/j.advnut.2023.05.013
Vancouver
Wang H, Wang Z, Zhang Z, Liu J, Hong L. β-Sitosterol as a Promising Anticancer Agent for Chemoprevention and Chemotherapy: Mechanisms of Action and Future Prospects. Advances in Nutrition. 2023;14(5):1085-1110. doi:10.1016/j.advnut.2023.05.013
BibTeX
@article{Wang2023,
author = {Wang, Haoyu and Wang, Zhi and Zhang, Zihui and Liu, Jingchun and Hong, Li},
title = {β-Sitosterol as a Promising Anticancer Agent for Chemoprevention and Chemotherapy: Mechanisms of Action and Future Prospects},
journal = {Advances in Nutrition},
year = {2023},
volume = {14},
number = {5},
pages = {1085--1110},
doi = {10.1016/j.advnut.2023.05.013}
}
EUVIMED